https://vivacellebio.com/the-lancet-journal-2024-01/2025-03-05T18:14:00+00:00https://vivacellebio.com/bio-partnering-2025/2025-02-14T18:05:48+00:00https://vivacellebio.com/selective-nitric-oxide-redistribution/2025-02-14T18:06:59+00:00https://vivacellebio.com/sepsis-awareness-month/2025-02-14T18:05:16+00:00https://vivacellebio.com/treating-septic-shock-with-nanoparticle-formulation-that-redistributes-nitric-oxide-with-dr-harven-deshield/2025-03-05T17:50:06+00:00https://vivacellebio.com/vivacelle-bio-enrolls-first-patient-in-phase-3-trial-of-hypovolemia-due-to-septic-shock-for-phospholipid-nanoparticle-based-vbi-s/2025-03-05T17:35:05+00:00https://vivacellebio.com/surge-in-septic-shock-care-vivacelles-innovative-approach/2025-03-05T17:40:49+00:00https://vivacellebio.com/vivacelle-bio-initiates-phase-3-trial/2025-03-05T17:54:04+00:00https://vivacellebio.com/vivacelle-bios-president-and-chief-innovation-officer-to-present-data-highlighting-the-companys-late-stage-clinical-programs/2025-03-05T18:00:58+00:00https://vivacellebio.com/sepsis-is-to-blame-for-40-year-old-mothers-unexpected-death/2025-03-07T14:38:47+00:00https://vivacellebio.com/vivacelle-bio-and-university-of-missouri-kansas-city-school-of-medicine-announce-groundbreaking-results-from-phase-2a-clinical-trial-of-vbi-s-for-refractory-hypotension-in-severe-septic-shock-patients/2025-03-07T14:38:05+00:00https://vivacellebio.com/sub-saharan-africa-strategy/2025-03-07T14:42:17+00:00https://vivacellebio.com/feds-hope-to-cut-sepsis-deaths-by-hitching-medicare-payments-to-treatment-stats/2025-03-07T14:52:30+00:00https://vivacellebio.com/hypovolemic-shock-market-to-exhibit-moderate-growth-rate-during-the-forecast-period-2022-2032/2025-03-07T15:02:07+00:00https://vivacellebio.com/vivacelle-bios-vbi-s-phase-iia-clinical-trial-meets-primary-and-secondary-endpoints-for-treating-hypovolemia-in-septic-shock-patients/2025-03-07T15:06:04+00:00https://vivacellebio.com/bprw-vivacelle-bio-announces-early-results-of-its-phase-iia-clinical-trial-of-vbi-s-for-improving-hypovolemia-due-to-sepsis/2025-03-07T15:09:54+00:00https://vivacellebio.com/septic-shock-market-is-expected-to-expand-at-a-healthy-growth-rate-by-2022-2032-states-delveinsight/2025-03-07T15:21:39+00:00https://vivacellebio.com/harven-deshield-in-bizcast-hq/2025-03-07T15:26:25+00:00https://vivacellebio.com/vivacelle-bio-biotech-executive-conversations/2025-03-07T15:28:52+00:00https://vivacellebio.com/sepsis-and-septic-shock-treatment-market-hitting-new-highs-by-2028/2025-03-07T15:32:47+00:00https://vivacellebio.com/vivacelle-bio-named-included-in-101-top-illinois-biotechnology-companies-and-startups-2021/2025-03-07T21:13:36+00:00https://vivacellebio.com/world-sepsis-pipeline-insight-2021-pipeline-product-profiles-therapeutic-assessment-pipeline-assessment-inactive-drugs-assessment-unmet-needs/2025-03-10T12:39:23+00:00https://vivacellebio.com/vivacelle-bio-receives-5-3-million-award-from-the-us-navy-for-a-clinical-trial-of-vbi-s-for-treatment-of-hypovolemia-of-septic-shock-due-to-covid-or-other-pathogens/2025-03-10T13:01:41+00:00https://vivacellebio.com/vivacelle-bio-given-the-business-expansion-award-by-the-metro-chamber-alliance-of-greater-fort-wayne/2025-03-10T12:47:44+00:00https://vivacellebio.com/black-doctor-says-he-has-developed-clinical-treatment-for-covid-19-patients-that-increases-oxygen-levels/2025-03-10T12:54:35+00:00https://vivacellebio.com/vbi-s-for-the-treatment-of-hypotension-in-hypovolemic-septic-shock-patients/2025-03-10T12:56:40+00:00https://vivacellebio.com/vivacelle-bio-provides-its-sepsis-treatment-for-covid-19-via-compassionate-use/2025-03-10T13:00:08+00:00https://vivacellebio.com/vivacelle-bio-granted-investigational-new-drug-ind-clearance/2025-03-10T13:03:37+00:00https://vivacellebio.com/a-new-organ-protective-volume-expanding-perfusion-vbi-1-fluid-based-on-phospholipid-nanoparticles-as-the-colloid/2025-03-10T13:09:01+00:00https://vivacellebio.com/ceo-of-vivacelle-bio-at-syracuse-college-of-law/2025-03-10T13:11:57+00:00https://vivacellebio.com/43north-finals-pitch-vivacelle-bio/2025-03-10T13:14:33+00:00